Medical Research & News


Advances are being made in improving diagnostic tools. Dr. Christiane Quelfeld presents what has become available and what the future holds.


New breakthroughs in research offer hope of better treatments and may offer insight into the causes of cutaneous lymphoma.

Modernizing Immunotherapy for Cutaneous T-cell Lymphoma

For decades, immunotherapy has been a cornerstone of systemic therapy for cutaneous T cell lymphoma (CTCL). It is therefore not surprising that modern immune-therapies, which target anti-tumor immunity in more sophisticated ways, have the potential to greatly improve our treatments for CTCL. 

Epigenetics & Biology of Cutaneous T-cell Lymphomas

These are exciting times in cutaneous T-cell lymphoma (CTCL) research. The hard work of laboratory and clinical investigators worldwide is starting to bear fruit, and a number of basic discoveries in the genetic and epigenetic foundations of CTCL are now being translated into novel therapies, with great impact for patients.

Medical Meeting Highlights: 3rd World Congress, T-Cell Lymphoma Forum and USCLC Annual Workshop

In a world that has 7,000 known rare diseases, with only 5% having any treatment available, the future of discovery and new treatment development in cutaneous lymphoma is promising. There is much hope for a brighter future for everyone living with this condition.

Industry Spotlight: Soligenix

Soligenix, Inc. recently to talk about their clinical trial for treating early stage cutaneous lymphoma. The treatment process uses a new topical photosensitizing agent (synthetic hypericin) and fluorescent light.

Industry Spotlight: miRagen Therapeutics

miRagen Therapeutics is a biotech company based in Boulder, Colorado that focuses on a specific cell mechanism of action called microRNA. miRagen is currently conducting a Phase I clinical trial in cutaneous lymphoma.

Industry Spotlight: Actelion Pharmaceuticals

Actelion Pharmaceuticals Medical Affairs Director Badri Rengarajan, MD and Associate Director Gaurav Sharma, Pharm.D, talk about two unique projects initiated over the last year: the PROv Study is a prospective, observational study that is currently open with plans to enroll 300 MF patients who will participate for a two-year timeframe. The team also developed of a quality of life measurement tool for early stage disease.

Industry Spotlight: Elorac

Elorac, Inc. is currently engaged in a Phase III clinical trial for topical naloxone, which targets itch in cutaneous lymphoma. Listen to the discussion to learn more about this innovative approach to managing the intense itch associated with the disease. 

Interleukin-13 is over-expressed in cutaneous T-cell lymphoma cells and regulates their proliferation

Cutaneous T-cell lymphomas (CTCLs) primarily affect skin and are characterized by proliferation of mature CD4+ T-helper cells. The pattern of cytokine production in the skin and blood is considered to be of major importance for the pathogenesis of CTCLs.
Key Points:
IL-13 is an autocrine factor for CTCL.
IL-13 and its receptors represent novel markers of CTCL malignancy and potential therapeutic targets for intervention.